There were no significant differences between individual classes of T2D medication, including insulins, biguanides, sulfonylureas, AGIs, DPP4 inhibitors, GLP1 inhibitors, SGLT2 inhibitors or TZDs after multiple hypothesis correction (FDR > 0.05). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.